2023-505261-84-00招募中3 期
EORTC-1809-STBSG: A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
European Organisation For Research And Treatment Of Cancer30 个研究点 分布在 10 个国家目标入组 180 人开始时间: 2023年8月31日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 180
- 试验地点
- 30
- 主要终点
- Disease free survival (which includes as events: distant progression on neoadjuvant treatment, local progression if not followed by R0/R1 surgery, non-operable tumours, local recurrence and/or distant metastases, R2 and death)
研究概览
简要总结
The primary objective of this study is to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of patients with high risk de-differentiated liposarcoma (DDLPS) and leiomyosarcoma (LMS) as measured by disease-free survival.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •STRASS 2: Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of retroperitoneal space or infra-peritoneal spaces of pelvis.
- •STREXIT 2: Patients enrolled in a Registry collecting data on primary RPS patients in the centres participating in STRASS 2 (e.g., RESAR) and who satisfy the above criteria.
- •Preferences for neoadjuvant chemotherapy in STRASS 2 substudy: All patients recruited to STRASS 2 in participating centres (Australia +/- international sites) that are able to read, comprehend and write in English at a sufficient level to complete study materials.
- •STRASS 2: Women of child bearing potential (WOCBP) must have a negative serum pregnancy test within 3 days prior to randomization. Note: a woman is considered of childbearing potential, i.e. fertile, if she is following menarche. She remains of childbearing potential until she becomes post-menopausal or permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 consecutive months without menses, a single FSH measurement is insufficient.
- •STRASS 2: WOCBP in both arms should use highly effective birth control measures, during the study treatment period and for at least 6 months after the last dose of chemotherapy or date of surgery (except for women receiving chemotherapy with ifosfamide who should continue contraception until 1 year after last day of treatment). A highly effective method of birth control is defined as a method which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly.
- •STRASS 2: For men in the experimental arm: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.
- •STRASS 2: Female subjects who are breast feeding should discontinue nursing prior to the first day of study treatment and until 6 months after the last study treatment.
- •STRASS 2: Before patient randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
- •STRASS 2: Unifocal tumour
- •STRASS 2: Resectable tumour: resectability is based on pre-operative imaging (CT-abdomen, potentially also with MRI) and has to be defined by the local treating sarcoma team. A patient is not considered resectable when the expectation is that only an R2 resection is feasible.
- •STRASS 2: Patient must have radiologically measurable disease (RECIST 1.1), as confirmed by imaging. CT thorax abdomen pelvis with IV contrast is the preferred imaging modality. In case of any contra-indications (medical or regulatory), it is allowed to perform a non-contrast CT thorax + MRI abdomen & pelvis.
- •STRASS 2: Collection of tumour tissue for central pathology review is mandatory. • For patients with LMS: if there is not enough tissue for assessing the grading, this is acceptable. If tumour tissue is not available for the central pathology review, patient will not be eligible. • If the biopsy was not done or the FFPE of the biopsy not available but at least 10 unstained slides or one pathological block are available for the central review, that will be considered as acceptable. • For the biopsy if fine needle aspiration (FNA) is performed instead of core needle biopsy (CNB) recommended by the standard guidelines, please contact the EORTC medical monitors for further evaluation.
- •STREXIT 2: Retrospectively all the patients observed and treated since the site activation for STRASS 2 to the opening of STREXIT2 can be included provided they consented before enrolment and the clinical data and/or CT/MRI images can be accessed.
- •STRASS 2: ≥ 18 years old (no upper age limit)
- •STRASS 2: WHO performance status ≤ 2
- •STRASS 2: Adequate haematological and organ function
- •STRASS 2: American Society of Anaesthesiologist (ASA) score < 3
- •STRASS 2: Collection of tumour tissue and blood samples for translational research is mandatory. • In case there is not enough tissue for TR, a new biopsy is not required and if the patient fulfils all other eligibility criteria, he/she will be eligible. • If the blood samples are not collected, patient will not be eligible. • If the patient refuses the collection of biomaterial for TR, patient will not be eligible even if he/she fulfils all other eligibility criteria.
- •STREXIT 2: Patients with histologically proven primary resectable localized high-risk DDLPS or LMS of retroperitoneal space or infra-peritoneal spaces of pelvis (as described in the inclusion criteria of STRASS 2) but for whom the list of eligibility criteria for the study is too restrictive.
- •STREXIT 2: Patients who meet all eligibility criteria of STRASS 2 but do not consent to randomization or are not enrolled for any other reason.
排除标准
- •Sarcoma originating from bone structure, abdominal or gynecological viscera
- •Known contraindication to imaging tracer and to MRI
- •Tumour grading not assessable from biopsy (except for LMS)
- •Extension through the sciatic notch or across the diaphragm
- •Metastatic disease
- •Any previous surgery (excluding diagnostic biopsy), radiotherapy or systemic therapy for the present tumour
- •Hypersensitivity to doxorubicin, ifosfamide, dacarbazine or to any of their metabolites or to any of their excipients
- •Cardiac disorders: Congestive heart failure, angina pectoris, myocardial infarction within 1 year before randomization, uncontrolled arterial hypertension defined as blood pressure ≥ 150/100 mm Hg despite optimal medical therapy, uncontrolled cardiac arrhythmia
- •Female patients who are pregnant or breastfeeding or female and male patients of reproductive potential who are not willing to employ effective birth control method.
- •Previous treatment with maximum cumulative doses (450mg/m² Doxorubicin or equivalent 900mg/m² Epirubicin) of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones
- •Active and uncontrolled infections
- •Vaccination with live vaccines within 30 days prior to study entry
- •Inflammation of the urinary bladder (interstitial cystitis) and/or obstructions of the urine flow.
- •Other invasive malignancy within 5 years, with the exception of adequately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤ 6prostate cancer.
- •Uncontrolled severe illness, infection, medical condition (including uncontrolled diabetes), other than the primary LPS or LMS of the retroperitoneum.
- •Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial
结局指标
主要结局
Disease free survival (which includes as events: distant progression on neoadjuvant treatment, local progression if not followed by R0/R1 surgery, non-operable tumours, local recurrence and/or distant metastases, R2 and death)
Disease free survival (which includes as events: distant progression on neoadjuvant treatment, local progression if not followed by R0/R1 surgery, non-operable tumours, local recurrence and/or distant metastases, R2 and death)
次要结局
- Overall survival
- Recurrence free survival
- Distant metastases free survival
- Cumulative incidence of local recurrences
- Cumulative incidence of distant metastases
- Radiological response to neoadjuvant chemotherapy according to RECIST
- Radiological response to neoadjuvant chemotherapy according to CHOI
- Pathological response
- Safety and toxicity of neoadjuvant chemotherapy
- Perioperative complications
- Late complications
- Health-Related Quality of life (EORTC QLQ-C30 + Item list from QLQ-STO22)
- Health utility, calculated from the collected patient-reported HRQoL data and patient demographics economics.
研究者
Stéphanie Kromar
Scientific
European Organisation For Research And Treatment Of Cancer
研究点 (30)
Loading locations...
相似试验
招募中
2 期
ABCSG 45: A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin is more effective than treatment with a standard chemotherapy (anthracycline/taxane-based) against a specific type of breast cancer (triple-negative) with a biologic characteristic (homologous recombination deficiency)2024-512821-10-00Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group90
进行中（未招募）
4 期
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as High or Intermediate Risk by a 14-Gene Prognostic Assay2024-511185-37-00Razor Genomics Inc., Razor Genomics Inc., Intergroupe Francophone De Cancerologie Thoracique300
尚未招募
不适用
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Breast CancerNCT07290166Fudan University42
招募中
2 期
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic CancerNCT07283705M.D. Anderson Cancer Center60
招募中
3 期
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerNCT07284849Incyte Corporation700